No comparative effect estimate was reported; failure rates were 32% and 12%.
No comparative effect estimate was reported; both arms had 16% failure.
No comparative effect estimate was reported; tabulated failure rates favored resin-modified GIC.
No comparative effect estimate was reported; the 7-second etching arm had a lower tabulated failure rate.
No comparative effect estimate was reported; failure rates were tabulated.
No comparative effect estimate was reported; cumulative failure rates were tabulated.
No comparative effect estimate was reported; failure rates were tabulated.
No comparative effect estimate was reported; cumulative failure was highest for glass carbomer.
No comparative effect estimate was reported; composite resin outperformed HVGIC in the review narrative.
No comparative effect estimate was reported; cumulative failure rates were tabulated.
No comparative effect estimate was reported; cavity disinfectant did not affect success in the review narrative.
No comparative effect estimate was reported; conventional GIC had a higher tabulated failure rate.
No comparative effect estimate was reported; the review described similar clinical performance.
No comparative effect estimate was reported; compomer had more favorable retention in the review narrative.
No eligible randomized clinical trials of bio-active restorative materials were found.
No comparative effect estimate was reported; both arms had 1.7% failure.
No comparative effect estimate was reported; failure rates were tabulated by arm.
No comparative effect estimate was reported; both arms had 0% failure.
It is very uncertain whether inhaled corticosteroids changes combined outcome of mortality or BPD at 36 weeks' PMA compared with placebo (very low certainty).
It is very uncertain whether inhaled corticosteroids changes mortality at 36 weeks' PMA compared with placebo (very low certainty).